Clinical Trials Directory

Trials / Completed

CompletedNCT05147207

SuperPath Versus Posterior Approach for THA

Supercapsular Percutaneously-Assisted Total Hip (SuperPATH®) Versus Conventional Posterior Approach for Total Hip Arthroplasty: A Prospective Randomized Controlled Study

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
45 (actual)
Sponsor
Queen's University · Academic / Other
Sex
All
Age
21 Years – 100 Years
Healthy volunteers
Not accepted

Summary

The SuperPATH approach is a minimally invasive approach for total hip arthroplasty. This project randomized patients to the SuperPath versus posterior approach. Outcomes examined included functional, VAS pain, narcotic utilization, perioperative outcomes, and radiographic component positions. Participants were followed for 2 years. The aim was to examine if the SuperPATH approach provided significant advantages over the posterior approach on functional testing or return to work for patients.

Detailed description

Background: The Supercapsular Percutaneously-Assisted Total Hip (SuperPATH) approach is a minimally invasive approach for total hip arthroplasty. It has been reported to show earlier mobilization, better gait kinematics, and short hospital length of stay. Our primary objective was to compare functional tests of timed up and go and timed stair climb preoperatively, at discharge, 2 weeks, and 6 weeks postoperatively. Secondary objectives included the return to function in weeks, Oxford hip scores, visual analog scale, narcotic utilization, perioperative outcomes, and radiographic component positions. Methods: Forty-six patients were randomized into two groups on the surgery day: the SuperPATH group (25 patients) and the Posterior group (20 patients). Outcomes examined included functional, VAS pain, narcotic utilization, perioperative outcomes, and radiographic component positions.

Conditions

Interventions

TypeNameDescription
PROCEDURESuperpath ApproachThis is a minimally invasive surgical approach for THA.

Timeline

Start date
2017-04-01
Primary completion
2019-05-01
Completion
2021-06-01
First posted
2021-12-07
Last updated
2022-04-20

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT05147207. Inclusion in this directory is not an endorsement.